# A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

> **NCT02140554** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 54 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **GENETIC:** lovo-cel

## Key facts

- **NCT ID:** NCT02140554
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-02
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-01-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140554, "A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02140554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*